Skip to main content
SpringerLink
Log in

Anakinra (Interleukin-1 Receptor Antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Rheumatoid arthritis (RA) has severe and lasting effects on quality of life. This review (1) describes the disease progression, disability, and joint destruction that seriously alter a patient’s quality of life, and (2) explains how the interleukin-1 receptor antagonist (IL-1Ra), anakinra, retards the progress of disease, thereby improving outcomes. Relevant articles were reviewed with a focus on RA, anakinra, and functional and quality-of-life outcomes. In randomized, controlled trials, the IL-1 Ra anakinra provided meaningful benefits for patients with active RA, such as decreased signs and symptoms of disease, slower radiographic disease progression, reduced disability, and improved health-related quality of life. The biologic agent, anakinra, provides to patients with RA a valuable treatment option that has a positive impact on both function and quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA. Detection of TNF-α but not TNF-β in rheumatoid arthritis synovial fluid and serum.Arthritis Rheum. 1988; 31: 1041–1045.

    Article  PubMed  CAS  Google Scholar 

  2. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma IL-1 levels with disease activity in rheumatoid arthritis.Lancet. 1988; 2: 706–709.

    Article  PubMed  CAS  Google Scholar 

  3. Tetta C, Camussi G, Modena V, DiVittorio C, Baglioni C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis.Ann Rheum Dis. 1990; 49: 665–667.

    Article  PubMed  CAS  Google Scholar 

  4. Shulze-Koops H, Davis LS, Kavanaugh AF, Lipsky PE. Elevated cytokine mRNA levels in the peripheral blood of patients with rheumatoid arthritis suggest different degrees of myeloid cell activation.Arthritis Rheum. 1997; 40: 639–647.

    Article  Google Scholar 

  5. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte derived IL-1 receptor antagonist.J Clin Invest. 1990; 85: 1694–1697.

    Article  PubMed  CAS  Google Scholar 

  6. Firestein GS, Berger AE, Tracey DE, et al. IL-1Ra protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium.J Immunol. 1992; 149: 1054–1062.

    PubMed  CAS  Google Scholar 

  7. Koch AE, Kunkel SL, Chensue SW, Haines GK, Strieter RM. Expression of IL-1 and IL-1ra by human rheumatoid synovial macrophages.Clin Immunol Immunopathol. 1992; 65: 23–29.

    Article  PubMed  CAS  Google Scholar 

  8. Deleuran BW, Chu CQ, Field M, et al. Localization of IL-1α, type 1 IL-1 receptor and IL-1ra in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis.Br J Rheum. 1992; 31: 801–809.

    Article  CAS  Google Scholar 

  9. Seckinger P, Klein-Nulend J, Alander C, Thompson RC, Dayer JM, Raisz LG. Natural and recombinant human IL-1 receptor antagonists block the effects of interleukin-1 on bone resorption and prostaglandin production.J Immunol. 1990; 145: 4181–4184.

    PubMed  CAS  Google Scholar 

  10. Firestein GS, Boyle DL, Yu C, et al. Synovial IL-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis.Arthritis Rheum. 1994; 37: 644–652.

    Article  PubMed  CAS  Google Scholar 

  11. Scott DL, Pugner K, Kaarela K, et al. The links between joint damage and disability in rheumatoid arthritis.Rheumatology. 2000; 39: 122–132.

    Article  PubMed  CAS  Google Scholar 

  12. Butt JH, Barthel JS, Moore RA. Clinical spectrum of upper gastrointestinal effects of NSAIDs: natural history, symptomatology and significance.Am J Med. 1988; 84: 5–14.

    Article  PubMed  CAS  Google Scholar 

  13. Corwin HL, Bonventre JV. Renal insufficiency associated with NSAID agents.Am J Kidney Dis. 1984; 4: 147–152.

    PubMed  CAS  Google Scholar 

  14. Spiegel BM, Targownik L, Dulai GS, Gralnek IM. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.Ann Intern Med. 2003; 138: 795–806.

    PubMed  Google Scholar 

  15. Puppo F, Murdaca G, Ghio M, Indiveri F. Emerging biologic drugs for the treatment of rheumatoid arthritis.Autoimmun Ref. 2005; 4: 537–541.

    Article  CAS  Google Scholar 

  16. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human IL-1ra.Arthritis Rheum. 1998; 41: 2196–2204.

    Article  PubMed  CAS  Google Scholar 

  17. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcomes Measures in Rheumatoid Arthritis Clinical Trials.Arthritis Rheum. 1993; 36: 729–740.

    Article  PubMed  CAS  Google Scholar 

  18. Paulus HE, Egger MJ, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease modifying anti-rheumatic drugs based on findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group.Arthritis Rheum. 1990; 33: 477–484.

    Article  PubMed  CAS  Google Scholar 

  19. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: the results of a twenty–four week, multicenter, randomized, double-blind, placebo-controlled trial.Arthritis Rheum. 2002; 46: 614–624.

    Article  PubMed  CAS  Google Scholar 

  20. Kineret® [package insert]. Thousand Oaks, Calif: Amgen Inc; October 2002.

  21. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis.Arthritis Rheum. 1980; 23: 137–145.

    Article  PubMed  CAS  Google Scholar 

  22. Pincus T, Sokka T. Quantitative measures and indices to assess rheumatoid arthritis in clinical trials and clinical care.Rheum Dis Clin North Am. 2004; 30: 725–751.

    Article  PubMed  Google Scholar 

  23. Bresnihan B, Cobby M. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis.Rheumatology (Oxford). 2003; 42(suppl 2): ii22-ii28.

    Article  Google Scholar 

  24. Emery P, Woolley JM, Chan WW. Improvement in health-related quality of life from anakinra therapy in patients with rheumatoid arthritis not using DMARDs [abstract]. Presented at: Annual European Congress of Rheumatology (EULAR 2001); June 16, 2001; Prague, Czech Republic.

  25. Nuki G, Bresnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.Arthritis Rheum. 2002; 46: 2838–2846.

    Article  PubMed  CAS  Google Scholar 

  26. Cohen SB, Woolley JM, Chan WW. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis.J Rheumatol. 2003; 30: 225–231.

    PubMed  CAS  Google Scholar 

  27. Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomized, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.Ann Rheum Dis. 2004; 63: 1062–1068.

    Article  PubMed  CAS  Google Scholar 

  28. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient’s perspective.J Rheumatol. 1993; 20: 557–560.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Allergy, and Immunology, Center for Innovative Therapy UCSD, 9500 Gilman Drive, 92093-0943, La Jolla, CA

    Arthur Kavanaugh MD (Professor of Medicine)

Authors
  1. Arthur Kavanaugh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kavanaugh, A. Anakinra (Interleukin-1 Receptor Antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. Adv Therapy 23, 208–217 (2006). https://doi.org/10.1007/BF02850127

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02850127

Keywords

Search

Navigation